Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 155Rituximab 148Etoposide 84fludarabine phosphate 73Peripheral Blood Stem Cell Transplantation 68Mycophenolic Acid 63Busulfan 62Filgrastim 59Melphalan 58Tacrolimus 54Whole-Body Irradiation 51Cytarabine 46fludarabine 45Radiotherapy 43Methotrexate 41Granulocyte Colony-Stimulating Factor 41Cyclosporine 41Vincristine 35Antilymphocyte Serum 35Carmustine 33Doxorubicin 29Prednisone 26Thiotepa 25Bendamustine Hydrochloride 24Methylprednisolone 22Ifosfamide 22Dexamethasone 22thymoglobulin 21sargramostim 20plerixafor 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Non-Hodgkin × Ice × Clear all
NCT01453205 2018-03-12

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

MedImmune LLC

Phase 2 Completed
187 enrolled 21 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00823719 2013-03-12

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

GlaxoSmithKline

Phase 2 Completed
61 enrolled 25 charts
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡